Arcus Biosciences to present new ARC-20 casdatifan data in kidney cancer at Oct. 20 investor event
Bitget2026/09/22 12:32- Arcus Biosciences set an in-person investor event for Oct. 20, 2026, to disclose new ARC-20 study data for casdatifan in kidney cancer.
- Results have not yet been presented; the update will cover performance across first-line combinations, a second-line combination, and late-line monotherapy.
- Management will frame whether casdatifan can serve as a backbone therapy across treatment lines, a key determinant of commercial positioning.
- Safety readouts are expected to support a first-line registrational trial planned for the fourth quarter of 2026.
- Updated evidence from a second-line regimen will align with a separate registrational study targeted to finish enrollment by end-2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
